Answers are grounded in this paper and cite their sources.
Objectives To evaluate the performance of Genewise MTBC/RIF (Genewise) in comparison with Xpert MTB/RIF (Xpert) assay and phenotypic drug susceptibility testing for detection of Mycobacterium tuberculosis (MTB) and rifampcin (RIF) resistance. Methods Respiratory specimens stored at the National Tuberculosis Reference Laboratory between January 2023 and December 2024 were tested using the MGIT 960, Genewise and the Xpert assay. Phenotypic RIF susceptibility testing was performed on culture-positive isolates using the minimal inhibitory concentration method. Diagnostic performance was assessed for MTB detection and rifampicin resistance identification. Results The Genewise assay demonstrated a sensitivity for MTB detection of 96.76% against liquid culture, 97.22% against microbiological reference standard (MRS) and over 99% against Xpert. For RIF resistance detection, both the Genewise and Xpert assay exhibited a sensitivity of 91.67% and a specificity of 98.52%. Head-to-head comparison showed near-perfect agreement between Genewise and Xpert for both MTB (κ = 0.851) and RIF resistance detection (κ = 1.0). The inverse correlation between Genewise CT values and Xpert bacterial load grades supported its semi-quantitative capability, and ROC curve analysis confirmed comparable diagnostic performance to Xpert (AUC = 0.988). Conclusion The Genewise MTBC/RIF assay is a rapid, automated molecular test that detects MTBC with high sensitivity and identifies RIF resistance with performance comparable to Xpert, making it well-suited to a complementary diagnostic tool.
No takes yet. Share an insight, caveat, or question.
Ou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: